Welcome to our dedicated page for Core Laboratories /DE/ SEC filings (Ticker: CLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Laboratories /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Laboratories /DE/'s regulatory disclosures and financial reporting.
Core Laboratories Inc. reported that shareholders approved all three proposals at its Annual Meeting held on May 12, 2026 in Houston, Texas. Two Class I directors, Harvey Klingensmith and Curtis Anastasio, were re-elected, each receiving strong majority support.
Shareholders also ratified the appointment of KPMG LLP as independent registered public accountant for the year ending December 31, 2026. In addition, an advisory vote approved the company’s executive compensation program, including the philosophy, policies and procedures described in its Compensation Discussion and Analysis.
Core Laboratories executive Mark Damian Tattoli, SVP, General Counsel & Secretary, exercised a restricted share award that delivered 250 shares of Common Stock on May 1, 2026. To cover tax obligations, 97 shares were disposed of at $14.07 per share, leaving 27,513.621 directly held shares.
He also holds shares indirectly, including 1,694.842 shares through a 401(k) plan and 20 shares in a custodial account. The filing notes multiple restricted share grants vesting annually over six years, contingent on continued service.
Core Laboratories Inc. reported weaker results for the quarter ended March 31, 2026, posting total revenue of $121.8 million, down 1% from a year ago and 12% from the prior quarter. Service revenue was $94.3 million and product sales were $27.5 million.
The company recorded an operating income of $1.9 million, sharply below $4.4 million a year earlier and $15.8 million in the prior quarter, reflecting lower activity, especially in international markets affected by Middle East and Russia/Ukraine conflicts, and higher costs. Net loss attributable to Core Lab was $0.8 million compared with a small loss a year ago and profit of $4.9 million in the previous quarter.
Operating cash flow was $4.0 million and free cash flow $0.5 million after $3.4 million of operating capital expenditures. Cash stood at $22.8 million, and gross long-term debt was $117.0 million, with a leverage ratio of 1.20 and interest coverage of 7.20 under its credit facility covenants. The company repurchased 51,781 shares for about $4.0 million and paid a quarterly dividend of $0.01 per share while remaining in compliance with all debt covenants.
Core Laboratories Inc. reported first quarter 2026 revenue of $121.8 million, down 11.9% from the prior quarter and 1.4% from a year earlier. GAAP operating income fell to $1.9 million and the company posted a GAAP net loss of $0.8 million, or $0.02 per diluted share.
Excluding stock compensation, write-downs and foreign exchange, operating income was $6.6 million and EPS was $0.06, both sharply lower than recent periods. Reservoir Description revenue was $81.9 million and Production Enhancement revenue was $39.9 million, with results pressured by Middle East conflict and severe weather in North America and Europe.
Free cash flow was $0.5 million on $4.0 million of operating cash flow and $3.4 million of operational capital spending. Net debt was $94.2 million with a leverage ratio of 1.20, and return on invested capital was 9.1%. The company repurchased 51,781 shares for about $0.9 million and declared a $0.01 quarterly dividend, payable June 1, 2026 to shareholders of record May 11, 2026. Second quarter 2026 revenue is projected at $123–$131 million and EPS at $0.06–$0.12.
Core Laboratories director Katherine Murray reported equity compensation activity. She received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to issuance terms and an elective deferral. Separately, 8,069 Restricted Shares completed a prior one-year vesting period and converted into 8,069 shares of Common Stock at no cost, bringing her directly held Common Stock to 29,290 shares.
Core Laboratories director Curt Anastasio reported routine equity compensation activity involving restricted shares and common stock. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance.
These Restricted Shares are subject to a deferral election under Treasury Regulation 1.409A-2, with vested shares to be distributed as common stock following his separation of service from the Board. He also exercised 8,069 Restricted Shares that had vested after a one-year vesting period ending April 1, 2026, receiving 8,069 shares of Common Stock and bringing his directly held common shares to 23,805. The filing shows acquisitions and exercises only, with no open-market buying or selling.
Core Laboratories Inc. director Harvey Robert Klingensmith reported equity compensation activity in company stock. He received a grant of 7,895 Restricted Shares on April 1, 2026 at a price of $0.00 per share. According to the terms, these Restricted Shares will vest at the end of a one-year vesting period on April 1, 2027, and are subject to a deferral election, with vested shares distributed as common stock after his separation of service from the Board. On the same date, 8,069 previously granted Restricted Shares vested at the end of their one-year vesting period and were converted into 8,069 shares of Common Stock at $0.00 per share. Following these transactions, Klingensmith directly holds 50,031 shares of Core Laboratories common stock.
Core Laboratories director Temeng Kwaku reported equity compensation and an option-style exercise. On April 1, 2026, he received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to the terms of issuance and a deferral election under Treasury Regulation 1.409A-2.
The filing also shows 8,069 Restricted Shares vested after a one-year period ending April 1, 2026 and were exercised into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, Kwaku directly holds 33,597 shares of Core Laboratories Common Stock.
Core Laboratories Inc. director Robert F. Martinovich reported equity-based compensation activity. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance and any deferral election.
Separately, 8,069 Restricted Shares vested at the end of a prior one-year vesting period on April 1, 2026 and were exercised into 8,069 shares of Common Stock, which he now holds directly. The filing shows only awards and an option-style conversion of restricted equity into common stock, with no open-market purchases or sales.
Core Laboratories director Martha Z. Carnes reported equity compensation activity involving restricted shares and common stock. She received a grant of 7,895 Restricted Shares on April 1, 2026, which will vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance.
On the same date, 8,069 previously granted Restricted Shares completed their one-year vesting period ending April 1, 2026 and were converted into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, she directly holds 54,397 shares of Core Laboratories common stock.